Accepted for Publication: April 30, 2012.
Published Online: November 26, 2012. doi:10.1001/jamaneurol.2013.592
Author Contributions:Study concept and design: Klein, Lennon, and Pittock. Acquisition of data: Klein, Aston, O’Toole, Quek, and Pittock. Analysis and interpretation of data: Klein, Lennon, McKeon, O’Toole, Quek, and Pittock. Drafting of the manuscript: Klein, O’Toole, and Pittock. Critical revision of the manuscript for important intellectual content: Klein, Lennon, Aston, McKeon, O’Toole, Quek, and Pittock. Statistical analysis: Klein and Quek. Obtained funding: Klein. Administrative, technical, and material support: Klein, Lennon, Aston, and O’Toole. Study supervision: Klein and Pittock.
Conflict of Interest Disclosures: Dr Pittock is a named inventor on patents (12/678 350 filed 2010 and 12/573 942 filed 2008) that relate to functional aquaporin-4/neuromyelitis optica–IgG assays and neuromyelitis optica–IgG as a cancer marker. Dr Pittock receives research support from Alexion Pharmaceuticals Inc, the Guthy Jackson Charitable Foundation, and the National Institutes of Health. Mayo Medical Laboratories/Mayo Collaborative Services Inc receive revenue for performing voltage-gated potassium channel complex and other autoantibody testing.
Funding/Support: The study was supported by the Mayo Foundation and the National Institutes of Health (grant K08 NS065007) and Mayo Clinic CTSA through grant UL1 RR024150 from the National Center for Research Resources, a component of the National Institutes of Health.
Additional Contributions: We thank Vickie Mewhorter, Amy Moses, BA, Jade Zbacnik, BA, and Debby Cheung, BS, for their technical assistance.